Epizyme Inc (NASDAQ:EPZM) has been assigned an average recommendation of “Buy” from the sixteen brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $23.64.
Several research analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Epizyme from a “buy” rating to a “hold” rating in a research report on Friday. BidaskClub raised shares of Epizyme from a “hold” rating to a “buy” rating in a research report on Thursday. Wedbush reissued an “outperform” rating and set a $25.00 price target (down previously from $26.00) on shares of Epizyme in a research report on Wednesday. Leerink Swann boosted their price target on shares of Epizyme from $22.00 to $24.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, SunTrust Banks reissued a “buy” rating and set a $27.00 price target on shares of Epizyme in a research report on Wednesday.
Shares of Epizyme (EPZM) traded down $1.00 during mid-day trading on Friday, hitting $18.75. 1,196,501 shares of the stock traded hands, compared to its average volume of 471,098. The firm has a market cap of $1,364.50, a PE ratio of -8.56 and a beta of 2.00. Epizyme has a 1 year low of $9.30 and a 1 year high of $21.40.
Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.05. The company’s revenue was down 100.0% on a year-over-year basis. sell-side analysts expect that Epizyme will post -2.44 earnings per share for the current fiscal year.
In other Epizyme news, COO Matthew Ros sold 72,264 shares of the company’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $16.63, for a total value of $1,201,750.32. Following the transaction, the chief operating officer now owns 74,867 shares of the company’s stock, valued at $1,245,038.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 25.20% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Teacher Retirement System of Texas acquired a new stake in shares of Epizyme during the fourth quarter worth about $202,000. Fox Run Management L.L.C. lifted its position in shares of Epizyme by 64.7% during the fourth quarter. Fox Run Management L.L.C. now owns 19,275 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 7,575 shares in the last quarter. Bailard Inc. acquired a new stake in shares of Epizyme during the fourth quarter worth about $251,000. MetLife Investment Advisors LLC acquired a new stake in shares of Epizyme during the fourth quarter worth about $263,000. Finally, JGP Global Gestao de Recursos Ltda. acquired a new stake in shares of Epizyme during the third quarter worth about $292,000. 86.09% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/04/08/brokerages-set-epizyme-inc-epzm-pt-at-23-00.html.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.